The Extension of HAPO Follow-up Study
Launched by CHINESE UNIVERSITY OF HONG KONG · Jul 25, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Extension of HAPO Follow-up Study is a research project designed to understand how certain health conditions during pregnancy, like high blood sugar and obesity, affect the health of children as they grow into young adults. The study is particularly focused on a group of mothers and their children who participated in earlier research when the children were around 7 to 14 years old. By looking at these families, researchers hope to learn more about how different levels of high blood sugar during pregnancy can influence a child's risk of developing health issues like diabetes and heart disease later in life.
To participate in this study, families need to be mother-child pairs who were part of the earlier HAPO follow-up study. However, children who were born prematurely (before 37 weeks of pregnancy), those who are not of Chinese descent, or whose mothers had certain test results revealed during pregnancy cannot join. If eligible, participants can expect to provide health information that will help researchers gain insights into the long-term effects of maternal health on children's well-being. This study is currently looking for participants, and it is an important step toward understanding and improving health outcomes for future generations.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Mother-child pairs who had been assessed in HAPO follow-up study at either 7 years or 11-14 years old
- Exclusion Criteria:
- • Children born preterm before 37 weeks of gestation
- • Non-Chinese
- • Mothers' OGTT results were unblinded during pregnancy
About Chinese University Of Hong Kong
The Chinese University of Hong Kong (CUHK) is a prestigious research institution renowned for its commitment to advancing medical science and improving healthcare outcomes. As a clinical trial sponsor, CUHK leverages its extensive academic resources and interdisciplinary expertise to conduct innovative research that addresses critical health challenges. The university fosters collaboration among leading researchers, healthcare professionals, and industry partners, ensuring rigorous study design and implementation. CUHK is dedicated to upholding the highest ethical standards in clinical research, with a focus on translating findings into tangible benefits for patients and the broader community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, Hong Kong, China, Hong Kong
Hong Kong, , Hong Kong
Patients applied
Trial Officials
Chi Chiu Wang
Principal Investigator
Chinese University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials